LONDON. 25 June 2015, 09:00 AM BST. Norgine B.V. announced today that it has entered an agreement with Apharm s.r.l. to distribute ZIVEREL™ in Spain, Australia and New Zealand.
ZIVEREL™ is a medical device (class III) used to maintain the integrity of the oesophageal mucosa to avoid the irritation of the oesophagus caused by stomach acid among other causes.
ZIVEREL™ is a combination of hyaluronic acid and chondroitin sulfate, which protects the oesophageal mucosa by an original and innovative mechanism.[i] The presence of a high bioadhesive capacity component (poloxamer 407) in the formulation increases the stability of contact between the chondroitin sulfate and hyaluronic acid in the surface of the wall of the oesophagus and contributes to the protective effect against the action of hydrochloric acid and pepsin produced by the stomach. Chondroitin sulfate also has an action that promotes the repair process of the oesophageal mucosa.
Peter Martin, COO at Norgine said: “We are delighted to be able to offer a new treatment option to patients who suffer from gastro oesophageal reflux symptoms, a condition which is on the rise and can have a significant impact on health-related quality of life and reduction in personal and work-related productivity.”
He added: “This recent transaction exemplifies our commitment to acquire further specialised innovative products to be maximised through our well established infrastructure.”
Gastro oesophageal reflux disease is prevalent worldwide, and disease burden may be increasing. It affects up to 20% of the Western population[ii] and is associated with a range of risk factors.
Notes to Editors:
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2014, Norgine’s total revenue was €296 million and the company employs over 1,000 people.
Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.
Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Apharm is a dynamic pharmaceutical company whose core business is the research and development of new products and registration of innovative patents that are licensed all over the world.
Apharm operates in the most important medical fields.
Constantly committed to improve people's life quality in terms of health and wellbeing, Apharm carries out an active role in discovering and treating pathologies of high social impact.
For more information, please visit www.apharm.it
Norgine Media Contacts:
Isabelle Jouin, T: +44 (0)1895 453643
Charlotte Andrews, T: +44 (0)1895 453607
Follow us @norgine
[i] Simone et al. Barrier effect of Esoxx®on esophageal mucosal damage: experimental study on ex-vivo swine model. Clin Exp Gastroenterology. 2012; 5: 103-17